Category

EN

NeuroVive Pharmaceutical AB Year End Report January – December 2019

By | EN, PR

STOCKHOLM, Feb. 19, 2020 /PRNewswire/ —

Important events in 2019

KL1333           

  • NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study           
  • NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study           
  • NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study

NV354           

  • NeuroVive initiates NV354 preclinical safety studies and scales up compound production

NeuroSTAT           

  • NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA           
  • NeuroSTAT receives Fast Track designation from the US Food and Drug Administration

Financials           

  • NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds           
  • NeuroVive receives SEK 28.2 Million in a directed new share issue

Strategy and communications           

  • NeuroVive updates its strategy and sharpens its focus on primary mitochondrial diseases           
  • NeuroVive hosts the company’s first Capital Markets Day           
  • NeuroVive hosts the Mitochondria Day for the second time

Other           

  • NeuroVive announces settlement in dispute with CicloMulsion AG

Important events after the reporting period           

  • NeuroVive proposes a rights issue of approximately MSEK 74 before issue costs. The rights issue is guaranteed to 90%. 

Financial information fourth quarter (Oct-Dec 2019)*           

  • Net revenues: KSEK 49 (5)           
  • Other operating income:  KSEK 1,000 (1,009)           
  • Loss before tax: KSEK 27,112 (19,978)           
  • Loss per share: SEK -0.15 (-0.25)           
  • Diluted loss per share: SEK -0.15 (-0.25)

Financial information full year 2019 (Jan-Dec 2019)*           

  • Net revenues: KSEK 34 (5)           
  • Other operating income:  KSEK 3,500 (2,461)           
  • Loss before tax: KSEK 77,000 (73,494)           
  • Loss per share: SEK 0.45 (0.94)           
  • Diluted loss per share: SEK 0.45 (0.94)

* APM Alternative perfomance measures, see definition on page 17 in the Report.

The complete Year End report is available for download below and through NeuroVive’s web site www.neurovive.com.

The information was submitted for publication, through the agency of the contact person set out below at 08:40 a.m. CET on 19 February 2020.

For more information please contact:
Erik Kinnman, CEO
+46 (0)46-275-62-20

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46-275-62-20 (switchboard)
[email protected]www.neurovive.com

For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/  

About NeuroVive 

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market’s Pink Open market in the US (OTC: NEVPF).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-year-end-report-january—december-2019,c3038975

The following files are available for download:

https://mb.cision.com/Main/6574/3038975/1196579.pdf

NeuroVive Pharmaceutical AB Year End Report January – December 2019

 

Are you a Corporate Representative of NeuroVive Pharmaceutical, an investor, or a member of the Business Press?



New Clarivate Analytics Report Reveals Emergence of Market Disrupters is Fragmenting Global Patent Landscape, Diluting Leading Innovators’ Invention Market Share

By | EN, PR

Innovation becoming more knowledge-intense and collaborative while the average number of inventors per patent record(1) rises according to latest Derwent Top 100 Global Innovators report

LONDON and PHILADELPHIA, Feb. 19, 2020 /PRNewswire/ — The global innovation environment is rapidly fragmenting as large organizations(2), share of global inventions drops to 18% in the face of competition from market disruptors. This is according to the Derwent Top 100 Global Innovators 2020 report, released today by Clarivate Analytics Plc (NYSE:CCC; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation.

The annual report, which can be downloaded here, identifies the world’s most innovative organizations. These businesses have successfully developed valuable patented inventions that also have strong commercialization potential based on market reach and impact on other downstream inventions.

For the first time, in 2020, the report’s analysis extends beyond the Top 100 to reveal three key trends:

  • Top 1,000’s shrinking invention market share: Six years ago, over a quarter (27%) of all inventions in Derwent World Patents Index™ (DWPI) came from the top 1,000 entities. Today, this has decreased to 18%. More and more patents are being incubated in smaller companies or even individual entrepreneurs and inventors. Large companies must learn to collaborate better and explore non-traditional partnerships or risk falling behind.
  • The need for collaboration: Innovation is becoming more knowledge intensive, and as technologies converge, base science, and engineering disciplines are more often combined, thereby requiring multiple layers of expertise. This is evident in the increase in the average number of listed inventors per DWPI patent record from 2.84 (in 2014) to 2.99 (in 2019).
  • Compression at the top: The threshold score for inclusion in the Derwent Top 100 Global Innovators has increased by over one-fifth (22% over a six-year period). The six new entrants to the Derwent Top 100 Global Innovators this year –Fujikura, HTC, Immersion, Microchip, Schneider Electric, and Tencent – have successfully navigated today’s competitive innovation landscape, and on average risen 250 places in the rankings since 2015.

"Today’s modern inventions, from phones and electric vehicles to medical devices, all require deeper and broader expertise, and for previously unrelated disciplines to work together," said Ed White, Head of Analytics, IP Group, Clarivate Analytics. "Large organizations that have traditionally dominated the innovation process must explore and embrace new ways of collaborating if they are to continue to thrive in a more complex and more fragmented ecosystem."

"Congratulations to the Top 100 Global Innovators, an excellent mix of organizations including many with extended legacies of driving innovation as well as those that have more recently pushed themselves to the forefront of today’s dynamic marketplace," said Jeff Roy, President, IP Group at Clarivate Analytics. "Together, they have built a culture of creating value based on ingenuity. And they have laid the bedrock for future innovation through the establishment and protection of their intellectual property.

Industry sector and regional snapshot
The Derwent Top 100 Global Innovators 2020 come from three continents and 14 countries/regions. The United States reclaimed the top spot with 39 organizations, followed by Japan with 32. Together, these two countries contributed almost three-quarters of this year’s Top 100 Global Innovators.

For industry sector representation, the Hardware & Electronics industries lead with 38 organizations, 3 more than last year, followed by Manufacturing & Medical with 16, and Telecoms and Software with 8 each.

Methodology
Now in its ninth year, Derwent Top 100 Global Innovators utilizes editorially enhanced, authoritative and accurate patent data from Derwent World Patents Index (DWPI) and Derwent Patent Citations Index (DPCI) to track innovation based on four indicators:

  1. Volume: The organization must have had at least 100 granted inventions (and more than 500 filed in total) in the past five years.
  2. Influence: The level of downstream impact by being highly cited externally by other organizations, and measured via the Derwent Patent Citations Index™ over the last five years, excluding citations from themselves.
  3. Success: A high ratio of success in obtaining patent grants.
  4. Globalization: The level of investment of a patent applicant in their invention, as tracked via the process of pursuing protection in all four of the key market patent offices of China, Europe, Japan, and the United States.

Additional findings and the full list of the Derwent Top 100 Global Innovators 2020 can be found here: https://clarivate.com/derwent/top100innovators/

About Derwent
Derwent™, a Clarivate Analytics company, powers the innovation lifecycle from idea to commercialization—with trusted patent data, applications and services including Derwent Innovation™, Derwent World Patents Index™, Derwent Patents Citation Index™ and Derwent Data Analyzer™. We build solutions for inventors, patent attorneys and licensing specialists at start-ups and the largest global innovators, legal professionals at the leading IP practices, and patent examiners at more than 40 patent offices. Our solutions are used to monitor technology trends and competitive landscapes, inform FTO opinions, prosecute patents, monetize and license assets and support litigation activities. For more information, please visit derwent.com.

About Clarivate Analytics                                  
Clarivate Analytics™ is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. We have built some of the most trusted brands across the innovation lifecycle, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. Today, Clarivate Analytics™ is on a bold entrepreneurial mission to help customers reduce the time from new ideas to life-changing innovations. For more information, please visit www.clarivate.com.

Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.

Media Contacts
Sofia Nogués, Senior External Communications Manager
[email protected]

Jack Wan, Director of Communications for Asia Pacific
[email protected]

1 Based on patents added to Derwent World Patents Index (DWPI), of the annual Global Top 100 Innovators
2 Top 1,000 entities as ranked each year for the Derwent Top 100 Global Innovators program

Logo – https://mma.prnewswire.com/media/455613/clarivate_logo_for_press_release_Logo.jpg

Related Links :

Home

Are you a Corporate Representative of Clarivate Analytics, an investor, or a member of the Business Press?



From Intern to Digital Transformation Leader: HKBN Proudly Appoints Samuel Hui as Chief Transformation Officer

By | EN, PR

HONG KONG, Feb. 19, 2020 /PRNewswire/ — HKBN Group ("HKBN" or the "Group") is proud to announce that it has appointed Samuel Hui in a newly created role of Chief Transformation Officer ("CTO"), responsible for driving the Group’s digital transformation, enhancing overall customer experiences and helping enterprise partners transform digitally.

Looking to leverage technology, data analytics and most importantly, Talent ingenuity to create seamless digital experiences tailored around consumers, this appointment facilitates HKBN and its 6,000+ Talent-force to transform as a Group and deliver exceptional – and constantly evolving – customer experiences for great business results.

Transforming HKBN with fresh leadership vision

Samuel’s appointment as CTO follows HKBN’s recent high-profile appointments of Sam Tan as Chief Innovation Officer ("CIO"), and CY Chan as Chief Talent & Purpose Officer ("CT&PO"). By design, these three newly created roles embody HKBN’s commitment to unleash 180-degree change, enhancing all aspects of its business starting from Talent thinking, innovation, purpose, and Co-Ownership to automation, digitalisation, customer engagement strategies and new agile ways of working together. The Transformation office will preside over three Centers of Excellences – namely Digital, Big Data & AI, and IoT – working with key strategic partners and HKBN itself to architect and deliver impactful customer experiences and business transformations.

From intern to CTO

Samuel’s HKBN journey is an extraordinary one that began in 2008, when he joined as a summer intern. After earning dual Bachelor Degrees in Mechanical Engineering from Dartmouth College in the United States, Samuel further matured by joining leading New York-based management consulting firm, Oliver Wyman, advising senior executives on transformation strategies.

In 2016, Samuel was headhunted by HKBN to relocate back to Kwai Chung, Hong Kong and make a difference for our home. Despite being hired without a specific role, on his first day at work, Samuel was given the task of helping start HKBN Mobile Services. His team launched the new product in just four short months and grew the business to over 200,000 subscribers in its first year. Through this accomplishment, HKBN evolved into a ‘quad-play’ business, offering unprecedented value across broadband, telephone, OTT and mobile service. Shortly after, Samuel created a new digital customer referral programme for HKBN. Following this success, he was promoted to lead a team of digital specialists overseeing the Group’s multichannel customer experience, as well as digital engagement and CRM strategy across both B2C and B2B customers.

HKBN Co-Owner and Group CEO NiQ Lai said, "This appointment, together with our new CIO and new CT&PO, means we now have 2x Sams + a CY to ensure our transformation happens. At HKBN, we eat what we cook before we sell it, i.e. transform ourselves first before we help our partners do so for theirs."

HKBN Co-Owner and CTO Samuel Hui added, "Transformation starts with Talents, rather than with technology. My role will be to drive a quantum improvement rather than incremental gains to the business, to augment our Talents rather than to replace them, and to upgrade them from riding a horse to driving a Maserati."

From an intern in 2008 to the company’s youngest CXO in 2020, Samuel is set for the next big step to drive HKBN Group’s digital transformation.


From an intern in 2008 to the company’s youngest CXO in 2020, Samuel is set for the next big step to drive HKBN Group’s digital transformation.

 

Speaking at the world’s biggest “cloud carnival” at Dreamforce 2019, Samuel (right) shared HKBN’s digital transformation journey, highlighting how Talent, not technology, is the most important factor for transformation success.


Speaking at the world’s biggest “cloud carnival” at Dreamforce 2019, Samuel (right) shared HKBN’s digital transformation journey, highlighting how Talent, not technology, is the most important factor for transformation success.

 

About HKBN Group

HKBN Group ("HKBN" or the "Group"), headquartered in Hong Kong with operations spanning Asia across Hong Kong, Singapore, Malaysia, mainland China and Macau, is a leading integrated telecom and technology solutions provider. Through three core brands, Hong Kong Broadband Network, HKBN Enterprise Solutions and JOS, the Group offers comprehensive one-stop information and communications technology ("ICT") services that include broadband, data connectivity, managed Wi-Fi, integrated cloud solutions, information security, mobile, voice communications, IoT, big data, enterprise applications, data centre facilities, business continuity, system integration and OTT entertainment. HKBN’s tri-carrier fibre infrastructure in Hong Kong covers 2.4 million residential homes and over 7,200 commercial buildings and facilities. Committed to creating a lasting positive impact to wherever it operates, HKBN embraces a Core Purpose to "Make our Home a Better Place to Live". The Group is managed by hundreds of Co-Owners (supervisory and management level Talents in the Group) who invested their savings to buy shares of HKBN Ltd. (SEHK Stock Code: 1310). For more information about HKBN, please visit www.hkbn.net/en.

Photo – https://photos.prnasia.com/prnh/20200219/2724358-1-a?lang=0
Photo – https://photos.prnasia.com/prnh/20200219/2724358-1-b?lang=0
Logo – https://photos.prnasia.com/prnh/20190604/2486375-1LOGO?lang=0

Related Links :

http://www.hkbn.net/en

Are you a Corporate Representative of HKBN Group, an investor, or a member of the Business Press?



Synopsys Completes Acquisition of Certain IP Assets from INVECAS

By | EN, PR

MOUNTAIN VIEW, California, Feb. 19, 2020 /PRNewswire/ — Synopsys, Inc. (Nasdaq: SNPS) today announced that it has completed its acquisition of certain IP assets from INVECAS. This acquisition broadens Synopsys’ DesignWare® Logic Library, Embedded Memory, General Purpose I/O, Analog, and Interface IP portfolio. The acquisition also adds a team of experienced R&D engineers to accelerate Synopsys’ physical IP roadmap across a range of process technologies to address customers’ evolving design requirements in markets such as consumer, IoT and automotive. INVECAS will retain its HDMI IP and ASIC Design Solutions.

The transaction is not material to Synopsys’ financials and the terms are not being disclosed.  

About DesignWare IP

Synopsys is a leading provider of high-quality, silicon-proven IP solutions for SoC designs. The broad DesignWare® IP portfolio includes logic libraries, embedded memories, embedded test, analog IP, wired and wireless interface IP, security IP, embedded processors and subsystems. To accelerate prototyping, software development and integration of IP into SoCs, Synopsys’ IP Accelerated initiative offers IP prototyping kits, IP software development kits and IP subsystems. Synopsys’ extensive investment in IP quality, comprehensive technical support and robust IP development methodology enable designers to reduce integration risk and accelerate time-to-market. For more information on DesignWare IP, visit www.synopsys.com/designware.

About Synopsys

Synopsys, Inc. (Nasdaq: SNPS) is the Silicon to Software™ partner for innovative companies developing the electronic products and software applications we rely on every day. As the world’s 15th largest software company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and is also growing its leadership in software security and quality solutions. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing applications that require the highest security and quality, Synopsys has the solutions needed to deliver innovative, high-quality, secure products. Learn more at www.synopsys.com/.  

Editorial Contacts:
Camille Xu
Synopsys, Inc.
[email protected]

Simone Souza
Synopsys, Inc.
[email protected]

Investor Contact:
Lisa Ewbank
Synopsys, Inc.   
[email protected]

 

Related Links :

http://www.synopsys.com

https://www.synopsys.com/zh-cn

Are you a Corporate Representative of Synopsys, Inc., an investor, or a member of the Business Press?



VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

By | EN, PR

Conference call to take place Friday, February 21, 2019 at 8:30 am Eastern time

AUSTIN, Texas, Feb. 19, 2020 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2019.

Event: VolitionRx Limited Fourth Quarter & Full Year 2019 Earnings and Business Update Conference Call
Date: Friday, February 21, 2020
Time: 8:30 a.m. Eastern time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID:  13699351

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition’s activities, including details of new and ongoing clinical trials, important events which have taken place in 2019, and milestones for 2020 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at http://ir.volition.com. In addition, a telephone replay of the call will be available until March 6, 2020. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13699351.

About Volition

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics(TM), which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition’s research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Nucleosomics(TM) is a trademark of Volition and its subsidiaries.

For more information about Volition, visit Volition’s website (http://www.volition.com) or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor, Volition

[email protected]

+44 (0)7557 774620

Scott Powell, Volition

[email protected]

+1 (646) 650 1351

Joseph Green, Edison Advisors

[email protected]

+1 (646) 653 7030

 

Cision View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-year-2019-earnings-conference-call-and-business-update-301006813.html

Related Links :

http://www.volitionrx.com

Are you a Corporate Representative of VolitionRx Ltd, an investor, or a member of the Business Press?



China XD Plastics Company Limited Regains Compliance With NASDAQ Annual Meeting Requirement

By | EN, PR

HARBIN, China, Feb. 18, 2020 /PRNewswire/ — China XD Plastics Company Limited (NASDAQ: CXDC) ("China XD Plastics" or the "Company"), one of China’s leading specialty chemical companies engaged in the development, manufacture and sale of polymer composite materials primarily for automotive applications, today announced that it has received the formal notification from the Listing Qualifications Department of The NASDAQ Stock Market ("NASDAQ") on February 13, 2020, informing the Company that it now complies with Listing Rule 5620, which requires that the Company holds an annual meeting of shareholders within twelve months after the end of a company’s financial year.

On January 2, 2020, NASDAQ notified the Company that it did not comply with Listing Rule 5620. On February 11, 2020, the Company held its annual meeting of shareholders.

About China XD Plastics Company Limited

China XD Plastics Company Limited, through its wholly-owned subsidiaries, develops, manufactures and sells polymer composites materials, primarily for automotive applications. The Company’s products are used in the exterior and interior trim and in the functional components of 31 automobile brands manufactured in China, including without limitation, AUDI, Mercedes Benz, BMW, Toyota, Buick, Chevrolet, Mazda, Volvo, Ford, Citroen, Jinbei and VW Passat, Golf, Jetta, etc. The Company’s wholly-owned research center is dedicated to the research and development of polymer composites materials and benefits from its cooperation with well-known scientists from prestigious universities in China. As of September 30, 2019, 601 of the Company’s products have been certified for use by one or more of the automobile manufacturers in China. For more information, please visit the Company’s English website at http://www.chinaxd.net, and the Chinese website at http://www.xdholding.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company’s growth potential in international markets; the effectiveness and profitability of the Company’s product diversification strategy; the impact of the Company’s product mix shift to more advanced products and related pricing policies;  the effectiveness, profitability, and the marketability of its the ongoing mix shift to more advanced products; the prospect of the Company’s Dubai facility, and the associated expansion into Middle East, Europe and other parts of Asia; the prospect of the Company’s Southwest China facility, the prospects of the Company’s Harbin facility, and its penetration into Northeast China; and its penetration into Southwest China; the Company’s projections of its revenues for performance in fiscal 2019.   These forward-looking statements can be identified by terminology such as "will," "expect," "project," "anticipate," "forecast," "plan," "believe," "estimate" and similar statements. Forward-looking statements involve inherent risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, the global economic uncertainty could further impair the automotive industry and limit demand for our products; fluctuations in automotive sales and production could have a material adverse effect on our results of operations and liquidity; our financial performance may be affected by the prospect of our Dubai facility and the associated expansion into Middle East, Europe and other parts of Asia; the withdrawal of preferential government policies and the tightening control over the Chinese automotive industry and automobile purchase restrictions imposed in certain major cities may limit market demand for our products; the slowing of Chinese automotive industry’s growth; the concentration of our distributors, customers and suppliers; and other risks detailed in the Company’s filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law.  Although the Company believes that the expectations expressed in these forward looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

 

Cision View original content:http://www.prnewswire.com/news-releases/china-xd-plastics-company-limited-regains-compliance-with-nasdaq-annual-meeting-requirement-301006605.html

Related Links :

http://www.xdholding.com

Are you a Corporate Representative of China XD Plastics Company Limited, an investor, or a member of the Business Press?



iClick Interactive Acquires Majority Interest in Optimal Power Limited

By | EN, PR

HONG KONG, Feb. 18, 2020 /PRNewswire/ — iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that, subject to certain closing conditions, it has agreed to acquire an 80% equity interest in Optimal Power Limited ("Optimal Power"), a subsidiary wholly owned by Creative Big Limited ("Creative Big"), both incorporated under the laws of the British Virgin Islands. Creative Big is wholly owned by Mr. Kenny Sin Nang CHIU ("Mr. CHIU"), a veteran businessman in Asia. Creative Big has secured a network of premium media licensing assets in countries including Singapore, Greater China (including Hong Kong), Australia, India, Indonesia, Philippines and Malaysia and as part of the transaction, Creative Big would inject the selected media licensing assets into Optimal Power.

Mr. CHIU, who has over 30 years of experience in the business field and has served as a member on boards of directors for a number of Hong Kong listed companies, across various industries. His strong network has helped build up the premium media licensing assets that Creative Big owns today. The Company will finance the acquisition through the issuance of certain number of American Depository Shares (the "ADSs") at a price of US$3.9 per ADS, which is 7% premium to the 14-day VWAP as of 14 February 2020. 

"This transaction represents an exciting step for our company. The success of such execution will not only give us the ability to enrich our offerings, but also a vital step toward our profitability improvement this year," said Jian "T.J." Tang, iClick’s Chief Executive Officer and Co-Founder.

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group Limited (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide including Asia and Europe.

For more information, please visit ir.i-click.com.

About Creative Big Limited

Creative Big provides digital marketing resources in various fields, including digital marketing channels, content marketing and social media marketing. In addition to acquisitions and strategic investments, Creative Big promotes the early development of new business models with its media resources and experience.

Safe Harbor Statement

This announcement contains forward-looking statements, including those related to the Company’s business strategies, operations and financial performance. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s fluctuations in growth; its success in implementing its mobile and new retail strategies, including extending its solutions beyond its core online marketing business; its success in structuring a CRM & Marketing Cloud platform; relative percentage of its gross billing recognized as revenue under the gross and net models; its ability to retain existing clients or attract new ones; its ability to retain content distribution channels and negotiate favorable contractual terms; market competition, including from independent online marketing technology platforms as well as large and well-established internet companies; market acceptance of online marketing technology solutions and enterprise solutions; effectiveness of its algorithms and data engines; its ability to collect and use data from various sources; ability to integrate and realize synergies from acquisitions, investments or strategic partnership; fluctuations in foreign exchange rates; and general economic conditions in China and other jurisdictions where the Company operates; and the regulatory landscape in China and other jurisdictions where the Company operates. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and other filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

In the United States:

iClick Interactive Asia Group Limited

Core IR

Lisa Li

John Marco

Phone: +86-21-3230-3931 #892

Tel: +1-516-222-2560

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/iclick-interactive-acquires-majority-interest-in-optimal-power-limited-301006526.html

Related Links :

http://ir.i-click.com

www.optaim.com

Are you a Corporate Representative of iClick Interactive Asia Group Limited, an investor, or a member of the Business Press?



Hailiang Education Releases 2020 Chinese New Year Chairman Letter

By | EN, PR

HANGZHOU, China, Feb. 18, 2020 /PRNewswire/ — Hailiang Education Group Inc. (Nasdaq: HLG) ("Hailiang Education", the "Company" or "we"), an education and management service provider of primary, middle, and high schools in China, today released a letter to shareholders from the chairman of the Company’s board of directors.

Dear Shareholders,

In 2019, Hailiang Education has adhered to its development goal of providing distinguished, specialized, and internationalized education. It has built a high-end education brand through its basic educational program, international program, and art educational program. In the fiscal year 2019, Hailiang Education has implemented a hybrid development strategy, which combines an asset-light model and strategic acquisitions, to improve brand recognition and explore market opportunities. We have achieved positive operating results, both from existing businesses and new business models. In fiscal year 2019, our revenue and net income increased by 28.2% and 36.8% respectively as compared to the previous fiscal year, which brought considerable investment returns to our shareholders. As of June 30, 2019, Hailiang Education has extended its network to 36 schools including 9 affiliated schools and 27 managed schools. The aggregate number of students enrolled in both our affiliated and managed schools has reached 61,109, among which 22,819 students came from our affiliated schools. As we continued to promote education internationalization, the number of students enrolled in the international program increased by 15% to 4,553, and the revenue generated by the international program increased by 25% to RMB410 million in the fiscal year 2019. At the same time, Hailiang Education has launched a variety of ancillary education services, such as educational training, study trip, and overseas study consulting services to diversify the Company’s businesses and increase its earnings.

The first half of the fiscal year 2020 has already passed. I am very excited and delighted to share the Company’s recent achievements and outlook with our shareholders.

Strengthen Talent Pool

With the mission of nurturing talents specializing in school management, Hailiang Education Cadre Army Institute (the "Cadre Institute") was founded in April 2019 and has provided professional training programs to teachers and other professionals working for Hailiang Education. The Cadre Institute currently has 47 mentors and 107 trainees. As of December 31, 2019, 41 teachers completed the trainee programs provided by the Cadre Institute, 14 of whom have been appointed to various intuitions within the Hailiang Education Group. In August 2019, we further established the Hailiang Great Teacher Development Institute ("the Great Teacher Institute") to implement the "Great Teachers Training Project," which is to train great teachers through initiatives such as mentor-trainees pairing and trainees’ three-year planning. As of December 31, 2019, the Great Teacher Institute has 26 internal mentors, 11 external mentors, and 86 trainees.

We also have kept on optimizing the talent structure of our teaching staff. For all the candidates we recruited on campus in 2019, 34% of them came from the Double-First Class University List, a selected list of Chinese universities and colleges which participate in the construction plan of world-class universities. Specifically, 30 candidates came from Tsinghua University and Peking University. For all the candidates we recruited in 2019, 26% of them had a master degree or above and 77% of them graduated from the Double-First Class University List.

Improved Teaching Quality Contributed to Remarkable Academic Results

With respect to the 2019 middle school entrance examination ("2018/2019 Zhongkao"), our students have achieved outstanding academic performance. Eighteen of our students placed in the Top 20 student ranking in Zhuji city, Zhejiang Province, while 275 of our students scored 685 points and above out of 770 points (the total score of the examination). In particular, one of our students scored 731 points, the highest score in Zhuji City, Zhejiang Province. With respect to the 2019 college entrance examination ("2018/2019 Gaokao"), one of our students achieved the highest score in Zhuji city, while two of our students were admitted into Tsinghua University and Peking University, respectively. Eighteen of our students passed the high-level universities’ independent admission examination, including Tsinghua University, Peking University, Fudan University, Shanghai Jiaotong University and Zhejiang University. In the 2019 graduate class of our affiliated schools, 284 students in our international programs applied for overseas universities, among which 283 students have received offers. Furthermore, 41% of these students received offers from the Global Top 100 Universities, such as Imperial College London and University College London. All 39 graduates of Hailiang Foreign Languages School (HFLS) received offers from the Global Top 100 Universities. Specifically, 72% and 26% of these offers were from the Global Top 30 Universities and the Global Top 10 Universities, respectively.

In the fiscal year 2019, one of our international students from our HSK program ("the Chinese Proficiency Test") was accepted by Tsinghua University and eight international students were accepted by Zhejiang University. Our graduates of HSK program also received admissions from other well-known universities in China, including Fudan University, Nanjing University, Southwest University of China, China Academy of Art, and Shanghai International Studies University.

In 2019, we also made progressive achievements in terms of academic competitions. Our students won a Gold Medal at the 35th National Physics Competition, as well as a Gold Medal and two Silver Medals at the 35th National Math Competition. In the "Five Major-Subject" Competition, which includes Math, Physics, IT, Chemistry, and Biology, 22 of our students were awarded first-prize, 65 of them were awarded second-prize, and 35 of them were awarded third-prize. Tsinghua University and Peking University have selected eight of our students who were outstanding in academic competition.

We value our students’ mental and physical health, demonstrated by multiple physical activates offered by us and our principle of encouraging students to participate in athletic contests. In 2019, our students have won the first prize of 14th Asian Shooting Championship, as well as five Gold Medals, five Silver Medals, and five Bronze Medals in the Zhejiang Youth Shooting Championship, respectively. Our students also won the second prize in the 2nd National Youth Games and National 7-man Rugby Championships respectively, the first prize in the junior high school championship of the Zhejiang Middle School Basketball League, and the second prize in the National U14 Men’s Basketball League.

Multiple Awards Received and Brand Recognition Increased

In the first half of the fiscal year 2020, Hailiang Education received multiple awards, including the "2019 Outstanding Brand Image Award" awarded by the Eighth China Finance and Economic Summit in 2019 and the "2019 Innovation Leadership Award" awarded by the 2019 China Finance Summit Winter Forum (2019 New Global Business Conference). Hailiang Education was listed on Barron’s "Top 50 Most Investment-Worthy Chinese Stocks in 2019."

Continue to Promote Cross-Regional School Cooperation, Steadily Expand the Training Services, and Diversify Business Development

On July 16, 2019, we entered into a cooperation agreement with the People’s Government of Chengguan District, Lanzhou City, Gansu Province to establish and operate an affiliated school named Lanzhou Hailiang Experimental School. The school will have a capacity of approximately 2,000 students and is composed of a primary school program and a middle school program. The school is expected to start operating in September 2020.

We signed a school cooperation agreement with the Education Bureau of Sihong County, Suqian City, Jiangsu Province on July 9, 2019, pursuant to which the Company has acquired the right to operate the Sihong Second Experimental School of Sihong County at Suqian city in Jiangsu. Furthermore, on January 12, 2020, we entered into a cooperation school operating agreement with the Management Committee of Suqian Economic and Technological Development Zone of Jiangsu Province National Development Zone, pursuant to which the Company has acquired the right to operate two public schools tentatively named "Xiamen Road School" and "Fumin Avenue School." These two schools will have a cumulative capacity of about 6,000 students and will be composed of primary and middle school programs. The two schools are expected to start operating in July 2020.

Besides, pursuant to the three-party strategic cooperation agreement we entered into with Hailiang Group and Hailiang Education Investment Group, we have a priority right to operate and manage such schools established by both Hailiang Group and Hailiang Education Investment Group through construction, merger and acquisition, and cooperation with third-parties. On November 27, 2019, Hailiang Group signed a cooperative school operating agreement with the Yuelong Sub-district office in Ninghai County, Ningbo City, Zhejiang Province to establish and operate a new school tentatively named Ninghai Public School. The school has a capacity of about 4,000 students and is composed of primary, middle and high school programs. The school is expected to start operating in the fall of 2021. On December 28, 2019, Hailiang Group signed a cooperative school operating agreement with the Wuhu Municipal People’s Government of Anhui Province to establish and operate a new affiliated school tentatively named Wuhu Hailiang Experimental School. The affiliated school will have a capacity of about 4,000 students and is composed of primary, middle and high school programs. The school is expected to partially start operating in September 2020.

In 2020, the Company will focus on K12 education market in China while exploring the education and training market sector specifically focusing on tutoring, English learning, and art education for children in China. The Company also plans to integrate its offline training programs with online courses and launch "Hailiang Mingyou", an online and offline extracurricular training brand. At present, we have initiated Hailiang Mingyou programs in Hangzhou and Zhuji City, Zhejiang Province. In the future, we will set up independent Hailiang Mingyou training institutions on each of our school campuses. Hailiang Mingyou will always commit itself to focus on product development and develop offline training and online courses in order to increase its market penetration further.

Enhance Our International Education Market Position, Upgrade Our International Enrollment Plan, And Implement Our Internationalized Development Strategy

In the fiscal year 2020, Hailiang Education started operating International Student College in January 2020 and will continue its efforts to recruit international students for its primary, middle and high school programs in order to increase the number of international students in its entire student body. The Company has also launched "The Belt and Road International Talents Study-in-China Philanthropic Program", which is a charitable project created to allow a larger number of international talents to study in China. The Company has built a proprietary international talents training model to attract international students to study at schools of Hailiang Education. Currently, the primary and middle school programs of International Student College offer Chinese-Western integration courses, which are mainly based on British courses. The high school program of our International Student College offers students different study plans and curriculums tailored to their interests in pursuing higher education programs in their senior year. For international students interested in applying to Chinese domestic universities, the high school program offers them an academic track preparing them for examinations necessary for applying to China’s top universities, such as the HSK level test. For students interested in applying to international universities, the high school program offers IGCSE and A-Level courses designed to increase students’ competitiveness in applicant pools and prepare them to enter top universities in the world.

Participate in Philanthropic Events to Fight Against The COVID-19[1] and Take on Its Responsibilities as a Public Company

Facing the outbreak of the COVID-19, Hailiang Education immediately established the "Coronavirus Prevention and Control Management Team" to handle the overall situation within the Company, devise and execute preventive plans , specify responsibilities at the school level, and implement comprehensive steps designed to prevent and control the development of the coronavirus at various levels. The Company also actively participated in donation events organized by Hailiang Group and Zhejiang Hailiang Charity Foundation. All the funds raised in such events will be used to fight against the epidemic, including procuring urgently needed supplies, providing public welfare fund for frontline medical staff and volunteers, and providing financial aids to families in need during the epidemic. Hailiang Education has promised to combat the epidemic and overcome the difficulties together with the whole Chinese society.

Relying on its abundant educational resources, outstanding facility capabilities, and technical advantages, the Company has set up an online platform – "Hailiang VIP Cloud Classroom" – to connect teachers with students. Connected through such platform, students are able to participate in online live lessons instructed by their teachers, and teachers are able to provide students with answers and guidance to any problem students have encountered during class. Hailiang Mingyou will also provide primary, middle, and high school students in China with free video courses covering various subjects. These video courses provide students with scientific and efficient guidance due to the epidemic.

The Company pays close attention to the ongoing epidemic, prepares for the new spring semester in advance, and provides an active appointment system that allow parents to register for our fall 2020 freshman school tour. We will confirm the visiting time with all the parents who registered for such tour based on the semester starting date determined by the Ministry of Education of the People’s Republic of China. As an industry leader in private education, Hailiang Education will leave its "Hailiang Education Faculty Recruitment Online Reservation Window" open and aim to release more openings for the public during this epidemic period.

On behalf of Hailiang Education, I would like to express my sincere gratitude to the students and parents for your trust in us, to the shareholders for your continuous support, and to the board members, management team, teachers and staff for your commitment and effort in the past year. Hailiang Education expects to firmly root its development in China’s private education industry, actively promotes the internationalization of our schools, and always keep our mission in mind. Meanwhile, Hailiang Education aims to continue to provide high-quality education and better educational services to its students while adhering to its fundamental principle of "everyone is talented and can effectively use their talents and potentials."

We will make efforts to achieve Mr. Feng Hailiang’s ideal, the founder of Hailiang Education, by helping students to study happily, to live healthily, to become knowledgeable, and to enter into their dream schools. At the same time, the Company will strive to fulfill parents’ satisfaction, to build a better brand image, to achieve more profitable results for our shareholders, and to make our faculty proud.

Ming Wang
Chairman and Chief Executive Officer
Hailiang Education Group Inc.

[1] COVID-19 (Corona Virus Disease 2019) is a virus (more specifically, a coronavirus) identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The latest situation summary updates are available on The Centers for Disease Control and Prevention’s web page COVID-19, Wuhan, China.

About Hailiang Education Group Inc.

Hailiang Education (Nasdaq: HLG) is one of the largest primary, middle, and high school educational service providers in China. The Company primarily focuses on providing distinguished, specialized, and internationalized education. Hailiang Education is dedicated to providing students with high-quality primary, middle, and high school, and international educational services and highly valuing the quality of students’ life, study, and development. Hailiang Education adapts its education services based upon its students’ individual aptitudes. Hailiang Education is devoted to improving its students’ academic capabilities, cultural accomplishments, and international perspectives. Hailiang Education operates multilingual programs including Chinese, English, Spanish, Japanese, Korean, and French. In addition, Hailiang Education has launched various diversified high-quality courses, such as Mathematical Olympiad courses, A-level courses, Australia Victorian Certificate of Education (VCE) courses, IELTS courses, TOEFL courses, as well as SAT courses. The Company has also formed extensive cooperative network more than 200 educational institutions and universities globally. Hailiang Education is committed to making great effort to provide its students with greater opportunities to enroll in well-known domestic and international universities to further their education. For more information, please visit http://ir.hailiangedu.com.

Forward-Looking Statement

This press release contains information about Hailiang Education’s view of its future expectations, plans, and prospects that constitute forward-looking statements. These forward-looking statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts in this announcement are forward-looking statements, including but not limited to the following: general economic conditions in China, competition in the education industry in China, the expected growth of the Chinese private education market, Chinese governmental policies relating to private educational services and providers of such services, health epidemics and other outbreaks in China, the Company’s business plans, the Company’s future business development, results of operations, and financial condition, expected changes in the Company’s revenue and certain cost or expense items, its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the number of students entrusted by schools, the successful integration of acquired companies, technologies and assets into its portfolio of software and services, marketing and other business development initiatives, dependence on key personnel, the ability to attract, hire, and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property, the outcome of ongoing, or any future, litigation or arbitration, including those relating to copyright and other intellectual property rights, and other risks detailed in the Company’s filings with the U.S. Securities and Exchange Commission (the "SEC"). Hailiang Education may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Hailiang Education’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, whether known or unknown, and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "will make," "will be," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "endeavor to," "is/are likely to," or other similar expressions. Further information regarding these and other risks is included in our annual report on Form 20-F and other filings with the SEC. All information provided in this press release is as of the date of this press release, and Hailiang Education undertakes no obligation to update any forward-looking statements, except as may be required under applicable law.

Contacts:

Mr. Litao Qiu
Board Secretary
Hailiang Education Group Inc.
Phone: +86-571-5812-1974
Email: [email protected]

Ms. Tina Xiao
President
Ascent Investor Relations LLC
Phone: +1-917-609-0333
Email: [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hailiang-education-releases-2020-chinese-new-year-chairman-letter-301005786.html

Related Links :

http://ir.hailiangedu.com

Are you a Corporate Representative of Hailiang Education Group Inc., an investor, or a member of the Business Press?



Henlius successfully held its fourth Scientific Advisory Board (SAB) meeting

By | EN, PR

SHANGHAI, Feb. 18, 2020 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK, Henlius), a global biologics company specialized in the discovery and development of high-quality and affordable antibodies for the treatment of patients with cancer and autoimmune diseases, recently held its fourth Scientific Advisory Board (SAB) meeting at Bay Area where the United States (US) Research and Development (R&D) site is located. Scientists from R&D groups at Shanghai, Taipei and California sites have attended the meeting either in-person or via tele-conference.

During this all-day SAB meeting, the topics focused on the presentation and discussion of Henlius’ most advanced research projects including scientific justification, competitive landscape, data update and future plans. The SAB members provided positive acknowledgement on the broad coverage of research pipeline, diverse mechanism and differentiated strategy, and impressive progress of key projects, as well as constructive feedbacks on project priority, biological insights and resource allocation.

Dr. Scott Liu, Henlius co-founder and Chief Executive Officer, started the meeting with an introduction of Henlius, focusing on Henlius’ vision and mission of affordable innovation, company history and strategy, commercialization plan and commitment to Research. Dr. Alvin Luk, Henlius Senior Vice President and Chief Medical Officer, provided an overview on Henlius Clinical strategy and pipeline, especially HLX10 anti-PD1 programs.

Special guest of the meeting Professor Ron Levy from Stanford University gave a lecture on the antibody therapy targeting tumor and in situ vaccination targeting immune system. Dr. Levy was the driving force behind the first FDA-approved monoclonal antibody for cancer treatment, Rituximab, which happens to be the first approved biosimilar in China and the first approved product from Henlius, HLX01. He also encouraged the collaboration between biotech and academia, leveraging each other’s strength in drug development and biology understanding. His sentiment was also unanimously shared by all the SAB members, guests and Henlius participants, and Henlius already had some specific collaboration initiatives with renowned researchers from academia that can be put into place soon.

"This was a very informative and productive SAB meeting. We are very excited to know the strong progress. Let’s try to find a date that is good for everyone around mid-2020 for the next SAB meeting," Professor Kun-Liang Guan, chairman of Henlius’ SAB acknowledged.

One of the SAB members, Professor Zihai Li, also commented, "Very impressive progress and a phenomenal meeting. The entire team was so engaging and energetic. Great things are bound to happen."

The meeting was concluded by a panel discussion on a variety of topics, an acknowledgement on the impressive progress, and emphasis on the research focus and collaboration. It is decided that the frequency of the SAB meeting shall be increased and the next SAB meeting is scheduled in mid-2020.

Biographies of Scientific Advisory Board Members

Dr. Kun-Liang Guan is a Distinguished Professor of Pharmacology at the University of California, San Diego. He obtained his BS (1982) at Hangzhou University, China and Ph.D. (1989) at Purdue University. From 1992-2007, Guan was a faculty at the University of Michigan. He received the MacArthur Fellowship, the American Society of Biochemistry and Molecular Biology Young Investigator Award, Distinguished Alumni Award from Purdue University, an AAAS Fellow, and is a highly cited researcher in Molecular Biology & Genetics (Thomson Reuters). Guan studies signaling mechanisms of cell growth and tumorigenesis, particular focusing on the mTOR and Hippo pathways.

Dr. Yiping Yang, Director, Division of Hematology, Professor of Medicine, the Ohio State University. Dr. Yang received his M.D. from Zhejiang University, and Ph.D. from University of Michigan. He then completed his postdoctoral training and Internal Medicine residency at the University of Pennsylvania, and his Medical Oncology fellowship at Johns Hopkins University. He is an ABIM-certified physician with clinical interest in lymphoma and leukemia. He has been selected as America’s top oncologist since 2008. He has also served as Associate Editor for Journal of Clinical Investigation (JCI) and JCI Insight. Funded by grants from National Institute of Health and private foundations, his research focuses on cancer immunology and immunotherapy, as well as gene therapy and viral immunity. He has published more than 100 peer-reviewed papers in journals including Science, Nature Immunology, Nature Genetics, Nature Medicine, Immunity, JCI, PNAS, etc.

Dr. Weiping Zou is a faculty at the University of Michigan. His research interests are in tumor immunopathology and immunotherapy. Over the past few years, his research team has achieved important insights into cancer immunopathogenesis. His research efforts demonstrate that the tumor microenvironment is comprised of immune cells that have been reprogrammed by active tumor-mediated processes to defeat tumor immunity and promote tumor progression in a highly effective manner. These studies have helped define the nature of immune responses in the cancer microenvironment, form the concept of immunosuppressive networks in the cancer microenvironment and provide significant insights into designing current immune therapies including inhibitory B7 checkpoint blockade (PD-L1, B7-H1) to treat cancer patients. The Zou laboratory is one of the most cited research teams in the field of Cancer Immunology. Dr. Zou is/was an editorial board member for 9 scientific journals. He has delivered more than 200 invited lectures. He serves as a reviewer for more than 15 funding agencies including NIH and DOD, and for more than 50 scientific journals including New England Journal of Medicine, Cell, Science, and Nature journals. He is the AACR Cancer Immunology Chairperson-elect 2018-2019.

Dr. Zihai Li is Klotz Memorial Chair in Cancer Research, Professor and Founding Director of the Pelotonia Institute for Immuno-Oncology at The Ohio State University James Comprehensive Cancer Center. He received his Ph.D. in Microbiology & Immunology from Icahn School of Medicine at Mount Sinai, New York. He completed his internal medicine residency in the Montefiore-Einstein Medical Center and his medical oncology fellowship at the Fred Hutchinson Cancer Research Center. Prior to his current position, he was chair of the Department of Microbiology and Immunology and co-leader of the Cancer Immunology Program at the NCI-designated Hollings Cancer Center at the Medical University of South Carolina (MUSC).  He is an expert in the field of GP96/GRP94 chaperone and played important roles in advancing HSP–based cancer vaccines. He recently uncovered the roles of platelets especially the TGFbeta-GARP axis on the platelets in immune tolerance and cancer immunotherapy, and discovered CNPY2 as a key initiator of the unfolded protein response. His laboratory has been continuously funded by NIH for the last two decades. Dr. Li has served multiple leadership roles in the American Society of Clinical Oncology (ASCO) and the Chinese American Hematologist and Oncologist Network (CAHON). He has been leading the effort to establish the Committee of Overseas Experts (COE) of the Chinese Society of Clinical Oncology (CSCO) and is the elected founding chair of the CSCO COE (2018-2020).

About Henlius Scientific Advisory Board Meeting (SAB)

The Scientific Advisory Board (SAB) of Henlius was established in May 2018, which consists of world-renowned scientists or physicians including Dr. Kun-Liang Guan, Dr. Yiping Yang, Dr. Weiping Zou and Dr. Zihai Li. These experts of biology, immunology and oncology have not only brought in professional insights on Henlius research strategy, but also provided scientific guidance on antibody discovery and development, helping Henlius to develop high-quality and affordable drugs to enhance the product pipeline and bring effective combo immunotherapies to patients.

About Henlius

Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process. Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization. On September 25, 2019, Henlius was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 2696.HK.

Until now, in addition to one product launched commercially, two products under New Drug Application (NDA) review and one product under Marketing Authorization Application (MAA) review, Henlius has conducted over 20 clinical studies for 14 products and 7 combination therapies worldwide. HLX01 (rituximab injection), the first product of Henlius, has been granted approval by the NMPA as the first approved biosimilar in China. HLX03 (adalimumab injection) and HLX02 (trastuzumab for injection) have their NDA under priority review by the NMPA. HLX02 is also the first China-manufactured biosimilar developed in a global setting. In June 2019, the MAA for HLX02 was accepted for review by EMA. Moreover, Henlius advances immuno-oncology combination therapies with proprietary mAbs including HLX10 (anti-PD-1 mAb) as backbone in combination with chemotherapy and other mAbs including HLX04 (bevacizumab biosimilar) and HLX07 (anti-EGFR mab). The global multi-center clinical trials are ongoing in various countries and regions worldwide.

 

Cision View original content:http://www.prnewswire.com/news-releases/henlius-successfully-held-its-fourth-scientific-advisory-board-sab-meeting-301006615.html

Related Links :

www.henlius.com

Are you a Corporate Representative of Henlius, an investor, or a member of the Business Press?



iClick Interactive Announces Early Convertible Bond Conversion by Key Investors

By | EN, PR

This early conversion will not only help enhance iClick’s balance sheet with a decreased debt level but also better align investors’ interests

HONG KONG, Feb. 18, 2020 /PRNewswire/ — iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that Marine Central Limited and Tech Famous Limited have voluntarily elected to convert an aggregate of $30 million, which is the entire outstanding principal amount of the convertible bonds the Company issued to them on November 11, 2019 and December 12, 2019, respectively (collectively, the "Notes"), into Class A ordinary shares, par value US$0.001 per share, of the Company at a price of US$7.8 per share, which is at an approximately 7% premium to the 14-day VWAP of the Company’s American Depositary Shares, each representing one-half of a Class A ordinary share of the Company, as of February 14, 2020.

"This early conversion sends a clear signal to the market that our important investors have the utmost confidence in our ability to execute and unlock shareholder value, would like to support our development, and believe the stock is currently underpriced.  This transaction will also serve to substantially reduce the debt on our balance sheet, availing capital to promote the growth of our core business, as well as various new corporate development initiatives," said Jian "T.J." Tang, iClick’s Chief Executive Officer and Co-Founder.

The Notes originally bore interest at the rate of 5.0% per annum and were convertible at the option of the holder into the Company’s ADSs, each representing one-half of a Class A ordinary share of the Company. The Notes were also callable at the option of the Company upon payment of the applicable redemption price.

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group Limited (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide including Asia and Europe.

For more information, please visit ir.i-click.com.

Safe Harbor Statement

This announcement contains forward-looking statements, including those related to the Company’s business strategies, operations and financial performance. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s fluctuations in growth; its success in implementing its mobile and new retail strategies, including extending its solutions beyond its core online marketing business; its success in structuring a CRM & Marketing Cloud platform; relative percentage of its gross billing recognized as revenue under the gross and net models; its ability to retain existing clients or attract new ones; its ability to retain content distribution channels and negotiate favorable contractual terms; market competition, including from independent online marketing technology platforms as well as large and well-established internet companies; market acceptance of online marketing technology solutions and enterprise solutions; effectiveness of its algorithms and data engines; its ability to collect and use data from various sources; ability to integrate and realize synergies from acquisitions, investments or strategic partnership; fluctuations in foreign exchange rates; and general economic conditions in China and other jurisdictions where the Company operates; and the regulatory landscape in China and other jurisdictions where the Company operates. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and other filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

In the United States:

iClick Interactive Asia Group Limited

Core IR

Lisa Li

John Marco

Phone: +86-21-3230-3931 #892

Tel: +1-516-222-2560

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/iclick-interactive-announces-early-convertible-bond-conversion-by-key-investors-301006474.html

Related Links :

http://ir.i-click.com

Are you a Corporate Representative of iClick Interactive Asia Group Limited, an investor, or a member of the Business Press?